---
title: "Pediatrix Medical | 8-K: FY2026 EBIT: USD 241.9 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292755271.md"
datetime: "2026-07-15T11:01:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292755271.md)
  - [en](https://longbridge.com/en/news/292755271.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292755271.md)
generator: "portal-rs"
---

# Pediatrix Medical | 8-K: FY2026 EBIT: USD 241.9 M

EBIT: As of FY2026, the actual value is USD 241.9 M.

#### Operational Metrics

For the second quarter of 2026, Pediatrix Medical Group, Inc. confirmed its payor mix remained stable and unchanged compared to recent historical trends and internal expectations . The company has not experienced unfavorable payor mix shifts reported elsewhere in the healthcare sector, nor has it seen material changes in other net revenue-related trends compared to recent historical periods .

#### Outlook / Guidance

Pediatrix Medical Group, Inc. reaffirms its previously reported full year 2026 outlook for Adjusted EBITDA, anticipating it will be in a range of $280 million to $300 million . The projected financial components for the year ended December 31, 2026, include Net income ranging from $152,100 thousand to $166,700 thousand, Interest expense of $33,500 thousand, Income tax provision between $56,300 thousand and $61,700 thousand, Depreciation and amortization expense of $24,800 thousand, and Transformational and restructuring related expenses of $13,300 thousand .

### Related Stocks

- [MD.US](https://longbridge.com/en/quote/MD.US.md)

## Related News & Research

- [Median Technologies updates financial communication calendar for H2 2026](https://longbridge.com/en/news/298619434.md)
- [Annaly Capital declares Q3 2026 dividend of $0.75 per share](https://longbridge.com/en/news/298499808.md)
- [Ecosuntek adds Q3 KPI update to 2026 corporate events calendar](https://longbridge.com/en/news/298712114.md)
- [Acteos delays H1 2026 results release to Oct. 28](https://longbridge.com/en/news/298618428.md)
- [Vivos Therapeutics amends 8-K to correct report date to Sept. 2, 2026](https://longbridge.com/en/news/298368513.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**